ClinicalTrials.gg
CompletedNCT01928628Updated Aug 28, 2013

Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients

A Phase 3 interventional study of Lercanidipine 10mg and Lercanidipine10mg /Valsartan 80mg in Hypertension, sponsored by LG Life Sciences. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-08-28.

Sponsored by LG Life Sciences (part of LG Chem) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
449
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 353 studies in Hypertension with a site in Korea, Republic of — 31 open to participants now, 41 under way, 11 of them phase 3. Hypertension · Korea, Republic of.

Enrollment
34th of 304
449 · median 110
Started
2012
with 22 others
Phase 3
92 of 353
9 open now
Registered
122nd of 353
by date

Among the 353 studies in Hypertension with a site in Korea, Republic of, this one is the 34th largest by enrollment of the 304 interventional ones that give a count, is one of 23 that started in 2012, is one of 92 in phase 3, and was the 122nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

31 of the 353 studies in Hypertension with a site in Korea, Republic of are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Hypertension with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study aims to compare and assess the efficacy and the safety of the combination agent of Lercanidipine and Valsartan and monotherapy of Lercanidipine alone in patients with essential hypertension

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged ≥ 20 to ≤75 years old
  • Patient with essential hypertension

Exclusion criteria

Exclusion Criteria:

  • When the BP level measured at screening was sitDBP>120 mmHg or sitSBP >180 mmHg
  • Patient with difference in repeatedly measured blood pressures from the selected arm at screening was sitSBP≥ 20mmHg or sitDBP ≥ 10mmHg
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
449 participants (actual)

Study arms

  • Active comparator
    Lercanidipine 10mg

    1 Tablet of Zanidip ® 10mg + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/V160 Placebo (8wks)

    Drug: Lercanidipine 10mg · Drug: Lercanidipine10mg /Valsartan 80mg Placebo · Drug: Lercanidipine 10mg /Valsartan 160mg Placebo

  • Experimental
    Lercanidipine10mg /Valsartan 80mg

    1 Tablet of Zanidip ® 10mg Placebo +1 Tablet of L10/V80 + 1 Tablet of L10/V160 Placebo (8wks)

    Drug: Lercanidipine10mg /Valsartan 80mg · Drug: Lercanidipin 10mg Placebo · Drug: Lercanidipine 10mg /Valsartan 160mg Placebo

  • Experimental
    Lercanidipine 10mg /Valsartan 160mg

    1 Tablet of Zanidip ® 10mg Placebo + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/ V160 (8wks)

    Drug: Lercanidipine 10mg /Valsartan 160mg · Drug: Lercanidipin 10mg Placebo · Drug: Lercanidipine10mg /Valsartan 80mg Placebo

Interventions

  • DrugLercanidipine10mg /Valsartan 80mg
  • DrugLercanidipine 10mg /Valsartan 160mg

    Drug page: Lercanidipine

  • DrugLercanidipin 10mg Placebo
  • DrugLercanidipine10mg /Valsartan 80mg Placebo
  • DrugLercanidipine 10mg /Valsartan 160mg Placebo
06

What researchers measure

Primary outcomes

  1. Change in mean sitDBP from week 0 to week 40

    Time frame: 40 weeks

Secondary outcomes

  1. Response rate at week 4 and 8

    Proportion (%) of patients with mean sitDBP\<90mmHg or proportion (%) of patients with mean reduction of sitDBP ≥10mmHg from week 0

    Time frame: 4 weeks and 8 weeks

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Na SH, Lee HY, Hong Baek S, Jeon HK, Kang JH, Kim YN, Park CG, Ryu JK, Rhee MY, Kim MH, Hong TJ, Choi DJ, Cho SW, Cha DH, Jeon ES, Kim JJ, Shin JH, Park SH, Lee SH, John SH, Shin ES, Kim NH, Lee SY, Kwan J, Jeong MH, Kim SW, Jeong JO, Kim DW, Lee NH, Park WJ, Ahn JC, Won KH, Uk Lee S, Cho JH, Kim SK, Ahn T, Hong S, Yoo SY, Kim SY, Kim BS, Juhn JH, Kim SY, Lee YJ, Oh BH. Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial. Clin Ther. 2015 Aug;37(8):1726-39. doi: 10.1016/j.clinthera.2015.05.512. Epub 2015 Jul 8. PubMed 26164786 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012 and a primary completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2013
First posted
Aug 27, 2013
Start
May 2012
Primary completionActual
Apr 2013
Last update
Aug 28, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01928628
Lead sponsor
LG Life Sciences
Responsible party
Sponsor
First posted
Aug 27, 2013
Start date
May 2012
Primary completion
Apr 2013
Last update
Aug 28, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lercanidipine

Start the discussion